SCHEMBL964946

SCHEMBL964946

CCC(C(=O)O)N1C(=O)C=CC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.44
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38
MEN1 O00255 1/20 0.38
TNNI3 P19429 1/20 0.38
TNNT2 P45379 1/20 0.38
TNNC1 P63316 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 5/20 0.38
MGLL Q99685 3/20 0.38
BLM P54132 2/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
WRN Q14191 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21065670 0.87 ALDH1A1 (0.42) DNMT1MAPTHPGDMEN1TNNI3
SCHEMBL28502906 0.84 DNMT1 (0.42) DNMT1MAPTHPGDMEN1KMT2A
SCHEMBL11975541 0.83 MGLL (0.38) DNMT1MAPTHPGDALDH1A1MGLL
SCHEMBL6567846 0.82 LMNA (0.47) DNMT1MAPTHPGDALDH1A1MGLL
SCHEMBL43970 0.81 PTPN1 (0.42) DNMT1HPGDALDH1A1MGLLPTGS1
SCHEMBL9464000 0.81 DNMT1 (0.45) DNMT1HPGDKMT2AALDH1A1NPSR1
SCHEMBL2382065 0.80 DNMT1 (0.42) DNMT1MAPTHPGDMEN1KMT2A
SCHEMBL9327777 0.80 SMN1; SMN2 (0.49) DNMT1
SCHEMBL3047987 0.80 MGLL (0.35) DNMT1MAPTHPGDALDH1A1MGLL
Potassium Ion SCHEMBL6473268 0.80 MGLL (0.35) DNMT1MAPTHPGDALDH1A1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029199-A Cysteine engineered antibodies and immunoconjugates 信达生物制药(苏州)有限公司 2026-05-12 CN claimed
WO-2025087855-A1 VACCINATION AGAINST THE AMYLOID-BETA 40 PEPTIDE ARACLON BIOTECH, S.L. (ES) 2025-05-01 WO claimed
CN-119823209-A Synthesis method of cyclic peptide containing maleimide acid 江苏金斯瑞生物科技有限公司 2025-04-15 CN claimed
CN-119771343-A Nano magnetic bead and preparation method and application thereof 苏州海狸生物医学工程有限公司 2025-04-08 CN claimed
WO-2025051254-A1 CYSTEINE ENGINEERED ANTIBODY AND IMMUNOCONJUGATE 信达生物制药(苏州)有限公司 2025-03-13 WO claimed
US-20240150407-A1 PEPTIDE FOR PREVENTING OR TREATING INFLAMMATORY DISEASES AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2024-05-09 US claimed
EP-4321528-A1 PEPTIDE FOR PREVENTING OR TREATING INFLAMMATORY DISEASES Ajou University Industry-Academic Cooperation Foundation (KR) 2024-02-14 EP claimed
US-20240043474-A1 ANTI-INFLAMMATORY PEPTIDE FOR PREVENTING OR TREATING ATOPIC DERMATITIS AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2024-02-08 US claimed
EP-4265630-A1 ANTI-INFLAMMATORY PEPTIDE FOR PREVENTING OR TREATING ATOPIC DERMATITIS Ajou University Industry-Academic Cooperation Foundation (KR) 2023-10-25 EP claimed
WO-2022215961-A1 PEPTIDE FOR PREVENTING OR TREATING INFLAMMATORY DISEASES 아주대학교산학협력단 2022-10-13 WO claimed
EP-2198301-A1 PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS Kode Biotech Limited (NZ) 2010-06-23 EP claimed
US-20100035799-A1 METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2010-02-11 US claimed
EP-1934609-A4 MAGNETIC NANOPARTICLE HAVING FLUORESCENT AND PREPARATION METHOD THEREOF AND USE THEREOF BITERIALS CO LTD (KR) 2009-06-24 EP claimed
WO-2009035347-A1 PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS WEINBERG CRISTINA-SIMONA (NZ) 2009-03-19 WO claimed
JP-2009508105-A 2009-02-26 JP claimed
EP-1934609-A1 MAGNETIC NANOPARTICLE HAVING FLUORESCENT AND PREPARATION METHOD THEREOF AND USE THEREOF Biterials Co., Ltd. (KR) 2008-06-25 EP claimed
WO-2007029980-A1 MAGNETIC NANOPARTICLE HAVING FLUORESCENT AND PREPARATION METHOD THEREOF AND USE THEREOF BITERIALS CO., LTD. (KR) 2007-03-15 WO claimed
US-20050239688-A1 Method for the synthesis of anthracycline-peptide conjugates UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2005-10-27 US claimed
EP-1525002-A1 METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2005-04-27 EP claimed
WO-2004011033-A1 METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2004-02-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035799-A1 METHOD FOR THE SYNTHESIS OF ANTHRACYCLINE-PEPTIDE CONJUGATES C9, DOHH, THOP1 DNMT1 3551/4885MAPT 4454/4885HPGD 2832/4885
US-20050239688-A1 Method for the synthesis of anthracycline-peptide conjugates C9, DOHH, THOP1 DNMT1 3551/4885MAPT 4454/4885HPGD 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.